Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been given an average rating of “Buy” by the nine research firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $13.42.

Several research analysts recently issued reports on the stock. BidaskClub downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 2nd. Robert W. Baird upped their price target on shares of Amicus Therapeutics from $12.00 to $15.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 12th. Cowen and Company reiterated a “buy” rating and set a $16.00 price target (up previously from $10.00) on shares of Amicus Therapeutics in a research report on Tuesday, July 11th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/08/amicus-therapeutics-inc-nasdaqfold-given-consensus-rating-of-buy-by-brokerages.html.

Amicus Therapeutics (FOLD) opened at 13.90 on Tuesday. The firm’s 50-day moving average is $11.40 and its 200 day moving average is $8.12. Amicus Therapeutics has a 1-year low of $4.41 and a 1-year high of $14.05. The firm’s market cap is $1.99 billion.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. During the same quarter last year, the company posted ($0.40) EPS. On average, equities analysts forecast that Amicus Therapeutics will post ($1.44) earnings per share for the current fiscal year.

In other Amicus Therapeutics news, insider Hung Do sold 29,914 shares of the business’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $8.00, for a total transaction of $239,312.00. Following the completion of the sale, the insider now directly owns 474,438 shares of the company’s stock, valued at approximately $3,795,504. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jay Barth sold 30,000 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $10.00, for a total value of $300,000.00. Following the sale, the insider now directly owns 64,184 shares of the company’s stock, valued at $641,840. The disclosure for this sale can be found here. 3.40% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in FOLD. Creative Planning boosted its stake in shares of Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,900 shares in the last quarter. Norges Bank purchased a new stake in shares of Amicus Therapeutics during the fourth quarter valued at $5,064,000. Goldman Sachs Group Inc. boosted its stake in shares of Amicus Therapeutics by 5.7% in the first quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock valued at $5,541,000 after buying an additional 41,711 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Amicus Therapeutics by 4.7% in the first quarter. Geode Capital Management LLC now owns 1,167,356 shares of the biopharmaceutical company’s stock valued at $8,323,000 after buying an additional 52,003 shares in the last quarter. Finally, Morgan Stanley boosted its stake in shares of Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after buying an additional 3,055,039 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.